David has worked at Alcobra since 2014 as their Chief Commercial Officer and now Interim CEO. He is responsible for all aspects of pre-launch marketing planning plus business development and product licensing. He also supports investor relations efforts and regularly speaks at health care investment conferences.

Prior to joining Alcobra, David worked at Shire for 10 years, most recently as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit. In that role, he led the commercial assessment of neuroscience licensing opportunities, managed commercial efforts on pipeline CNS products, and led long-term strategic planning process. Previously, he served as Global General Manager for Vyvanse, where he led the launch of Vyvanse and led global expansion efforts including successful establishment of a partnership in Japan and launches in Canada and Brazil. Prior to that, David served as Vice President of Marketing for all of Shire's ADHD products.

From 1990–2004, David worked at Merck, where he held positions of increasing responsibility in marketing, sales, market research, and business development. In addition to his knowledge and experience with CNS medications, David's therapeutic expertise includes osteoporosis, migraine, and hyperlipidemia. He has been directly involved with the marketing of five prescription drug brands with annual sales in excess of 1B USD each.

Outside of work, David serves as Chairman of the Board of the Philadelphia Education Fund, a non-profit dedicated to improving the quality of education in Philadelphia’s public schools.

David graduated magna cum laude with a bachelor's degree in Economics and Computer Science from Duke University. He earned an MBA in Marketing from Duke University’s Fuqua School of Business.